In October 2025, we had 27 million won in capital and a hypothesis. The hypothesis was that GLP-1 medications — tirzepatide, semaglutide — were going to reshape the Korean pharmaceutical market faster than the regulatory apparatus or the traditional distribution networks were prepared for.
Five months later, we had done 3.2 billion won in GLP-1 wholesale revenue. In April 2026, we completed the acquisition of 도팜인, a pharmaceutical wholesale company. By June, we held six to eight percent of Korean tirzepatide distribution.
The hypothesis was not wrong.
What people misunderstand about GLP-1
Most coverage of GLP-1 medications focuses on weight loss. This is understandable — the before-and-after photographs are dramatic, the celebrity endorsements are visible, and weight is the outcome that gets clicks.
But metabolic researchers understand GLP-1 as something larger: a class of medications that addresses insulin resistance, the underlying dysfunction that connects obesity, type 2 diabetes, fatty liver disease, cardiovascular disease, and possibly cognitive decline. Weight loss is the visible effect. The metabolic correction is the mechanism.
This reframing matters for how you think about the market. GLP-1 is not a diet drug with a large addressable market. It is metabolic infrastructure — the pharmaceutical equivalent of the shift from reactive to preventive healthcare — with a much larger one.
The supply chain problem
In Korea in late 2025, the GLP-1 supply chain was fragmented. Manufacturers were allocating limited supply through legacy wholesale networks that had not been designed for the demand curve that materialized after the first wave of media coverage.
Clinics and pharmacies that wanted to prescribe and dispense tirzepatide could not reliably source it. The people who needed it were waiting. The distribution infrastructure was the constraint.
We entered at this constraint.
With 27 million won — roughly 19,000 dollars — we placed our first inventory positions. We had existing relationships in the pharmaceutical supply chain through our pharmacy operations. We had a logistics capability we had built for other purposes. We had a team that could move faster than traditional wholesale operations because we had not inherited the slow institutional habits that make legacy distributors slow.
The six hundred percent
Three months after acquiring 도팜인 in April 2026, wholesale revenue had grown six hundred percent. The company that was losing money when we acquired it was generating 1.2 billion won in monthly gross profit.
The driver was not a clever financial structure. It was operational speed — the ability to source, allocate, and deliver faster than competitors — combined with the clinic relationship network we had been building through our pharmacy locations.
What comes after GLP-1
The more interesting question is what the GLP-1 moment signals beyond itself.
Medications that address metabolic dysfunction at the root level will continue to emerge. The populations taking them will need supportive supplements — specifically, the protein and micronutrient support that GLP-1 side effects tend to deplete. We launched GLPH — a supplement line designed specifically for GLP-1 users — in August 2026.
The infrastructure we built to distribute tirzepatide becomes the infrastructure for whatever comes next in metabolic medicine.
That is what we mean by metabolic infrastructure. Not a drug. A position.